Catumaxomab: Clinical development and future directions
Open accessAbstract
Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the European Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites. The marketing authorization holder Fresenius Biotech GmbH developed catumaxomab (Removab(®)) together with its partner TRION Pharma GmbH, Germany. It is the first substance worldwide with a regulatory label for the treatment of malignant ascites due to epithelial carcinomas. Since the peritoneum is of mesothelial origin and therefore lacks EpCAM expression, the intraperitoneal administration of catumaxomab is an attractive targeted immunotherapeutic approach. Catumaxomab is able to destroy EpCAM positive tumor cells in the peritoneal cavity known as the main cause of malignant ascites. In addition, catumaxomab is a potential therapeutic option for several primary tumors since the EpCAM molecule is expressed on the majority of epithelial carcinomas. This review focuses on the clinical development of catumaxomab and indicates future directions.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The first approved bsAbs are catumaxomab and blinatumomab.
“This is best exemplified by the first approved bsAbs, catumaxomab (a bsAb binds both CD3 on cytotoxic T cells and EpCAM on human adenocarcinomas,88) and blinatumomab (a CD19 × CD3 targeting bispecific scFv antibody fragment.89)”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 32 · Cited by 274
Research works printed but not linked: 1
- Sadeghi B, Arvieux C, Glehen O, Rivoire M, Baulieux J, Fontaumard E, et al. Peritoneal Carcinomatosis from Non-Gynecologic Malignancies. Cancer 2000; 88:358- 63.
- Authors
- Linke, R., Klein, A., & Seimetz, D.
- Affiliations
- Neovii Biotech (Germany) (DE)
- ORCID
- Linke, Rolf
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 2
- Issue
- 2
- Pages
- 129-136
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC2840231
- OpenAlex
- W2060209794
- Cited by
- 274
- References
- 32
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 27 · 2023: 22 · 2022: 25 · 2021: 30 · 2020: 10 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 13 · 2015: 14 · 2014: 16 · 2013: 27 · 2012: 17
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- mAbs (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- catumaxomab, bispecific antibodies, trifunctional antibody, malignant ascites, EpCAM, epithelial cancers, intraperitoneal administration, targeted immunotherapy, drug approval, clinical development
- MeSH terms
- Epithelial Cell Adhesion Molecule, Animals, Antigens, Neoplasm, Antineoplastic Agents, Carcinoma, European Union, Humans, Immunotherapy, Peritoneal Neoplasms, Cell Adhesion Molecules, Antibodies, Bispecific, Drug Discovery, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
